Autolus Therapeutics (NASDAQ:AUTL) Given New $10.00 Price Target at Truist Financial

Autolus Therapeutics (NASDAQ:AUTL – Free Report) had its price objective trimmed by Truist Financial from $11.00 to $10.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other analysts have also recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and […]

Apr 2, 2025 - 08:17

Autolus Therapeutics (NASDAQ:AUTL – Free Report) had its price objective trimmed by Truist Financial from $11.00 to $10.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other analysts have also recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and […]